Characteristics of Patients Who Visit Urologic Outpatient Department via Health Promotion Center

다국어 초록 (Multilingual Abstract)

Purpose: Health examination is one of the methods to make the diagnosis of benign prostatic hyperplasia. To evaluate factors leading to the visit to the outpatient department (OPD) in patients at the health promotion center (HPC) who did not undergo urology treatment.Materials and Methods: This observational study was based on data from an HPC database of 2,700 patients who underwent transrectal ultrasound between March 2018 and February 2021. Of these, 264 patients visited OPD. Factors affecting OPD visits, such as colonoscopy at HPC and daily fluid intake, were evaluated. Logistic regression analysis was used to identify the independent risk factors to predict the visit to OPD.Results: Age (p<0.001) and diagnosis of overactive bladder (p<0.001) were significantly correlated with the severity of the total International Prostate Symptom Score (IPSS); however, colonoscopy evaluation at HPC and daily fluid intake did not correlate. Prostate volume (PV) (p=0.002) and total IPSS (p<0.001) were identified as predictive factors for the visit at OPD via HPC. The cutoff value of total IPSS and PV were 12 points and 26.7 cm³. The total IPSS (8–11) at HPC group presented higher total IPSS at OPD and the total IPSS (12–19) at HPC group showed lesser total IPSS at OPD (1.9±2.8 vs. -1.0±4.2, p=0.008).Conclusions: Twelve or more total IPSS is a significant factor that determines the OPD visit. At HPC, the primary care physician should be considered to recommend OPD to patients who have 12 or more total IPSS and 26.7 cm³ or more PV at the same time.

참고문헌 (Reference)

1 Black L, "The psychometric validation of a US English satisfaction measure for patients with benign prostatic hyperplasia and lower urinary tract symptoms" 7 : 55-, 2009

2 Egan KB, "The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms : prevalence and incident rates" 43 : 289-297, 2016

3 Becher E, "The effects of dutasteride, tamsulosin, and the combination on storage and voiding in men with benign prostatic hyperplasia and prostatic enlargement : 2-year results from the Comb ination of A vodart and T amsulosin study" 12 : 369-374, 2009

4 Roehrborn CG, "The benign prostatic hyperplasia registry and patient survey : study design, methods and patient baseline characteristics" 100 : 813-819, 2007

5 Kim SC, "Tadalafil administered once daily for treatment of lower urinary tract symptoms in Korean men with benign prostatic hyperplasia : results from a placebo-controlled pilot study using Tamsulosin as an active control" 3 : 86-93, 2011

6 Kawabe K, "Silodosin, a new α1A-adrenoceptorselective antagonist for treating benign prostatic hyperplasia : results of a phase III randomized, placebo-controlled, double-blind study in Japanese men" 98 : 1019-1024, 2006

7 Takahashi S, "Safety and effectiveness of mirabegron in male patients with overactive bladder with or without benign prostatic hyperplasia : a Japanese post-marketing study" 13 : 79-87, 2021

8 Loutradis C, "Role of hypertension in kidney transplant recipients" 35 : 958-969, 2021

9 Kristal AR, "Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia : results from the prostate cancer prevention trial" 177 : 1395-1400, 2007

10 Roehrborn CG, "Quantifying the contribution of symptom improvement to satisfaction of men with moderate to severe benign prostatic hyperplasia : 4-year data from the CombAT trial" 187 : 1732-1738, 2012

11 Yu HJ, "Non-inferiority of silodosin to tamsulosin in treating patients with lower urinary tract symptoms(LUTS)associated with benign prostatic hyperplasia(BPH)" 108 : 1843-1848, 2011

12 Power RE, "Medical treatment of BPH : an update on results" 2 : 6-14, 2004

13 Barry MJ, "Measuring diseasespecific health status in men with benign prostatic hyperplasia" 33 (33): AS145-55, 1995

14 Park JS, "Impact of metabolic syndrome-related factors on the development of benign prostatic hyperplasia and lower urinary tract symptoms in Asian population" 98 : e17635-, 2019

15 Ma H, "Exploring the effect of virtual reality relaxation environment on white coat hypertension in blood pressure measurement" 116 : 103721-, 2021

16 Kirby RS, "Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia : the Prospective European Doxazosin and Combination Therapy(PREDICT)trial" 61 : 119-126, 2003

17 Barkin J, "Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia : 2-year data from the CombAT trial" 103 : 919-926, 2009

18 Fawzy A, "Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients : a multicenter study" 154 : 105-109, 1995

19 Andersen M, "Double-blind trial of the efficacy and tolerability of doxazosin in the gastrointestinal therapeutic system, doxazosin standard, and placebo in patients with benign prostatic hyperplasia" 38 : 400-409, 2000

20 El Din KE, "Correlation between uroflowmetry, prostate volume, postvoid residue, and lower urinary tract symptoms as measured by the International Prostate Symptom Score" 48 : 393-397, 1996

21 Wimmer NJ, "Comparison of pulse wave analysis between persons with white coat hypertension and normotensive persons" 9 : 513-517, 2007

22 Siami P, "Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement : the CombAT(Combination of Avodart® and Tamsulosin)trial rationale and study design" 28 : 770-779, 2007

23 McVary KT, "BPH : epidemiology and comorbidities" 12 (12): S122-S128, 2006

24 Williams B, "2018 ESC/ESH Guidelines for the management of arterial hypertension" 77 : 71-159, 2019